2023-12-11 11:15:05 ET
More on Pasithea Therapeutics
- Pasithea stock jumps 12% on update for anti-tumor drug PAS-004
- Financial information for Pasithea Therapeutics
For further details see:
Pasithea stock soars as high as 190% on preclinical data2023-12-11 11:15:05 ET
For further details see:
Pasithea stock soars as high as 190% on preclinical dataMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Pasithea Therapeutics Corp. Company Name:
KTTA Stock Symbol:
Market:
Pasithea Therapeutics Corp. Website:
MIAMI, June 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis typ...
-- PAS-004 inhibition of in vitro NRAS cell lines does not plateau in contrast to approved MEK inhibitors -- -- PAS-004 inhibition of in vitro NRAS cell lines is greater than selumetinib and binimetinib and similar to trametinib -- -- PAS-004 shows superior activity versus selumetinib and...